Jump to section
To democratize healthcare on a global scale by enabling the field of Oculomics - a new branch between radiology and laboratory medicine on the diagnostic tree.
Tesseract is attempting to massively disrupt the health prediction and diagnostics field through AI powered retinal scanning technology, which until now has mostly been based on blood sampling.
The company points out that the retina is the only place where arteries, veins, capillaries, and nerves can be seen directly – something which it claims can be leveraged to recognize signs of a range of diseases such as Alzheimer’s, Parkinsons, anemia and heart disease. Indeed, there’s been a considerable amount of research done in the last few years which back these claims up.
Though not yet available on the US market, the fact that Tesseract’s latest fundraise was oversubscribed highlights the excitement surrounding the company. This is no doubt helped by its founder Dr. Jonathan Rothberg, a serial health tech entrepreneur and winner of the National Medal of Technology and Innovation in 2015.
There are still plenty of obstacles to overcome as Tesseract seeks FDA approval and international clearance, but this is an extremely innovative company with huge potential.
Steph
Company Specialist at Welcome to the Jungle
Apr 2021
$80m
SERIES B
Jonathan Rothberg
(Founder)Founder & chairman of 4Catalyzer, which incubated Tesseract. Serial health entrepreneur who founded, among others, AI Therapeutics, DNA sequencing company Quantum-Si (IPO), and ultrasound company Butterfly Network. Awarded the National Medal of Technology and Innovation by Barack Obama.